Sleep Apnea Truck Driver Study

Among Toronto Rehab’s international leading areas of study is sleep apnea research.  As our population ages, we recognize that more people will be touched by conditions such as cancer, heart disease, stroke and diabetes – all of which, we are now learning, are linked to sleep apnea.

Sleep apnea affects approximately 10% of the adult population. In North America, this translates to 18 million affected, 90% of whom have not been formally diagnosed.

In particular, sleep apnea poses a major concern for the Canadian trucking industry, contributing to a higher risk of motor vehicle accidents, poor work performance and other serious health conditions. 

Toronto Rehab researchers are leading the way in developing innovative new technologies and treatments to better equip us to respond to the growing number of people living with sleep apnea and its related health conditions. 

Our scientists are spearheading the first-ever trucking industry-focused study of sleep apnea in Canada. Partnering with the trucking and insurance industries, this study will reform and improve Canadian road safety.  Your support of this Industry Initiative will help Toronto Rehab: 

  • Measure and understand the prevalence and impact of sleep apnea in the Ontario and Canadian trucking industry using Toronto Rehab’s new at-home diagnostic device, BresoDx™ (formerly ApneaDx). Learn more
  • Measure and analyze the cost and benefit of diagnosing and treating sleep apnea in the trucking industry.
  • Positively influence policies and standards governing sleep apnea issues for the trucking industry based on solid evidence
Currently there is no reliable scientific research providing evidence on the scope of the problem of sleep apnea in the Canadian trucking industry. Your generosity will help Toronto Rehab undertake world-leading research and patient care that will impact the future of health care in Ontario, Canada and around the world.

To join your industry partners in supporting this initiative, please contact:

Arlene Manankil-Boyce, Director of Development
416-597-3422 ext. 3545
arlene.boyce@uhn.ca

Learn more about Research at Toronto Rehab